Toronto Dominion Bank Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NYSE
The Toronto-Dominion Bank and TD Securities Inc. have filed a Schedule 13G, reporting beneficial ownership of 6.9% of UroGen Pharma Ltd.'s ordinary shares.
NYSE
The Toronto-Dominion Bank and TD Securities Inc. have updated their beneficial ownership filing for Stoke Therapeutics, Inc., reporting a combined 4.9% stake.
NYSE
Vanguard Capital Management has reported beneficial ownership of 5% of Toronto-Dominion Bank's common stock as of June 30, 2026.
NYSE
The Toronto-Dominion Bank and its subsidiary TD Securities Inc. have reported beneficial ownership of 5.4% of Stoke Therapeutics, Inc. common stock as of March 31, 2026.
NYSE
The Toronto-Dominion Bank and TD Securities Inc. have filed a Schedule 13G, reporting beneficial ownership of 5.4% of UroGen Pharma Ltd.'s ordinary shares as of March 31, 2026.
NYSE
The Toronto-Dominion Bank has filed a Schedule 13G, reporting beneficial ownership of 3,025,945 shares, or 3.7%, of PTC Therapeutics, Inc. common stock as of March 31, 2026.
NYSE
The Toronto-Dominion Bank has filed a Schedule 13G, reporting beneficial ownership of 5.5% of Immatics N.V. ordinary shares as of March 31, 2026.
NYSE
The Toronto-Dominion Bank and TD Securities Inc. have jointly filed a Schedule 13G, reporting beneficial ownership of 6.2% of Greenbrier Companies Inc. common stock as of March 31, 2026.
NYSE
The Toronto-Dominion Bank has reported a 4.9% beneficial ownership stake in UroGen Pharma Ltd., holding over 2.3 million ordinary shares.
NYSE
The Toronto-Dominion Bank has reported a 5.2% beneficial ownership stake in PTC Therapeutics, Inc., holding 4,138,215 shares.
NYSE
The Toronto-Dominion Bank has reported a 6% beneficial ownership stake in Greenbrier Companies Inc. common stock.
NYSE
The Toronto-Dominion Bank has reported a 6.9% beneficial ownership stake in UroGen Pharma Ltd., holding over 3.19 million ordinary shares.
NYSE
The Toronto-Dominion Bank has reported a 5.8% beneficial ownership stake in Stoke Therapeutics, Inc., holding 3,173,258 shares of common stock.
NYSE
Bank of Montreal and its affiliates have disclosed a beneficial ownership of 4.94% of Toronto-Dominion Bank's common shares as of June 30, 2025.
NYSE
SCHEDULE 13G/A: BlackRock Amends Passive Stake in Toronto Dominion Bank to 4.7%
BlackRock, Inc. has filed an amended Schedule 13G, disclosing a 4.7% passive beneficial ownership stake in Toronto Dominion Bank as of March 31, 2025.
NYSE
Bank of Montreal and its affiliates have filed a Schedule 13G, reporting a collective beneficial ownership of 5.1% in the common shares of Toronto-Dominion Bank as of December 31, 2024.